proteinase k lactic acid  (Millipore)


Bioz Verified Symbol Millipore is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 80

    Structured Review

    Millipore proteinase k lactic acid
    Proteinase K Lactic Acid, supplied by Millipore, used in various techniques. Bioz Stars score: 80/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/proteinase k lactic acid/product/Millipore
    Average 80 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    proteinase k lactic acid - by Bioz Stars, 2020-03
    80/100 stars

    Related Products / Commonly Used Together

    proteinase k
    phenylmethylsulfonyl fluoride

    Images

    Related Articles

    Isolation:

    Article Title: Immunological and Metabolic Features of Pancreatic Ductal Adenocarcinoma Define Prognostic Subtypes of Disease
    Article Snippet: Conditioned media was isolated from ~80–90% confluent established pancreatic cancer cell lines 72 hours post-split, or post-transfection, centrifuged at 4000 RPM for 10 minutes, and filtered with a 0.45 micron syringe filter to remove contaminating cells and debris before use. .. For proteinase K and lactic acid experiments, following conditioned media collection, samples were treated with proteinase K (50μg/ml) for 30 minutes at 37°C followed by phenylmethylsulfonyl fluoride (PMSF, 5mM) for 1 hour at room temperature to inactivate proteinase K. Lactic acid (Sigma Aldrich, St. Louis, MO) was added at 8mM.

    Incubation:

    Article Title: Immunological and Metabolic Features of Pancreatic Ductal Adenocarcinoma Define Prognostic Subtypes of Disease
    Article Snippet: For polarization assays, following incubation in the presence of PMA, adherent THP-1 cells were washed and differentiation media was replaced with fresh supplemented RPMI with or without 50% conditioned media. .. For proteinase K and lactic acid experiments, following conditioned media collection, samples were treated with proteinase K (50μg/ml) for 30 minutes at 37°C followed by phenylmethylsulfonyl fluoride (PMSF, 5mM) for 1 hour at room temperature to inactivate proteinase K. Lactic acid (Sigma Aldrich, St. Louis, MO) was added at 8mM.

    Cell Culture:

    Article Title: Immunological and Metabolic Features of Pancreatic Ductal Adenocarcinoma Define Prognostic Subtypes of Disease
    Article Snippet: For macrophage differentiation assays, THP-1 cells were cultured for 72 hours in the presence of 50ng/ml phorbol 12-myristate 13-acetate (PMA) or 50% conditioned media, as indicated. .. For proteinase K and lactic acid experiments, following conditioned media collection, samples were treated with proteinase K (50μg/ml) for 30 minutes at 37°C followed by phenylmethylsulfonyl fluoride (PMSF, 5mM) for 1 hour at room temperature to inactivate proteinase K. Lactic acid (Sigma Aldrich, St. Louis, MO) was added at 8mM.

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 97
    Millipore granzyme b inhibitor ii
    <t>Granzyme</t> B inhibition abrogates cetuximab-mediated ADCC in HCT116 cells HCT116-Empty, HCT116-miR-143 or HCT116-miR-145 cells were exposed to 100 μg/ml cetuximab or PBMCs (20:1) alone, or co-treatment of cetuximab together with PBMCs, or vehicle (control). Cetuximab-mediated ADCC was evaluated using the xCELLigence system and LDH release assay in ( A ) cells pre-treated for 2 h with 500 ng/ml of neutralizing antibody to Fas (ZB4), or in ( B ) cells exposed to PBMCs pretreated for 30 min with 100 μM Ac-IETD-CHO. ( C ) Caspase -3/7 activity was determined as described above. Results are expressed as (A, B) mean ± SEM, or (C) mean ± SEM fold-change to respective untreated cells. ** p
    Granzyme B Inhibitor Ii, supplied by Millipore, used in various techniques. Bioz Stars score: 97/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/granzyme b inhibitor ii/product/Millipore
    Average 97 stars, based on 2 article reviews
    Price from $9.99 to $1999.99
    granzyme b inhibitor ii - by Bioz Stars, 2020-03
    97/100 stars
      Buy from Supplier

    99
    Millipore granzyme b
    <t>Granzyme</t> B inhibition abrogates cetuximab-mediated ADCC in HCT116 cells HCT116-Empty, HCT116-miR-143 or HCT116-miR-145 cells were exposed to 100 μg/ml cetuximab or PBMCs (20:1) alone, or co-treatment of cetuximab together with PBMCs, or vehicle (control). Cetuximab-mediated ADCC was evaluated using the xCELLigence system and LDH release assay in ( A ) cells pre-treated for 2 h with 500 ng/ml of neutralizing antibody to Fas (ZB4), or in ( B ) cells exposed to PBMCs pretreated for 30 min with 100 μM Ac-IETD-CHO. ( C ) Caspase -3/7 activity was determined as described above. Results are expressed as (A, B) mean ± SEM, or (C) mean ± SEM fold-change to respective untreated cells. ** p
    Granzyme B, supplied by Millipore, used in various techniques. Bioz Stars score: 99/100, based on 15 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/granzyme b/product/Millipore
    Average 99 stars, based on 15 article reviews
    Price from $9.99 to $1999.99
    granzyme b - by Bioz Stars, 2020-03
    99/100 stars
      Buy from Supplier

    Image Search Results


    Granzyme B inhibition abrogates cetuximab-mediated ADCC in HCT116 cells HCT116-Empty, HCT116-miR-143 or HCT116-miR-145 cells were exposed to 100 μg/ml cetuximab or PBMCs (20:1) alone, or co-treatment of cetuximab together with PBMCs, or vehicle (control). Cetuximab-mediated ADCC was evaluated using the xCELLigence system and LDH release assay in ( A ) cells pre-treated for 2 h with 500 ng/ml of neutralizing antibody to Fas (ZB4), or in ( B ) cells exposed to PBMCs pretreated for 30 min with 100 μM Ac-IETD-CHO. ( C ) Caspase -3/7 activity was determined as described above. Results are expressed as (A, B) mean ± SEM, or (C) mean ± SEM fold-change to respective untreated cells. ** p

    Journal: Oncotarget

    Article Title: miR-143 or miR-145 overexpression increases cetuximab-mediated antibody-dependent cellular cytotoxicity in human colon cancer cells

    doi: 10.18632/oncotarget.7010

    Figure Lengend Snippet: Granzyme B inhibition abrogates cetuximab-mediated ADCC in HCT116 cells HCT116-Empty, HCT116-miR-143 or HCT116-miR-145 cells were exposed to 100 μg/ml cetuximab or PBMCs (20:1) alone, or co-treatment of cetuximab together with PBMCs, or vehicle (control). Cetuximab-mediated ADCC was evaluated using the xCELLigence system and LDH release assay in ( A ) cells pre-treated for 2 h with 500 ng/ml of neutralizing antibody to Fas (ZB4), or in ( B ) cells exposed to PBMCs pretreated for 30 min with 100 μM Ac-IETD-CHO. ( C ) Caspase -3/7 activity was determined as described above. Results are expressed as (A, B) mean ± SEM, or (C) mean ± SEM fold-change to respective untreated cells. ** p

    Article Snippet: To inhibit granzyme B, PBMCs were pre-incubated with 100 μM of Granzyme B inhibitor II, Ac-IETD-CHO (Calbiochem, Merck Millipore, Massachusetts, USA) for 30 min at 37°C, before target cell treatment.

    Techniques: Inhibition, Lactate Dehydrogenase Assay, Activity Assay

    Granzyme B inhibition abrogates cetuximab-mediated ADCC in HCT116 cells HCT116-Empty, HCT116-miR-143 or HCT116-miR-145 cells were exposed to 100 μg/ml cetuximab or PBMCs (20:1) alone, or co-treatment of cetuximab together with PBMCs, or vehicle (control). Cetuximab-mediated ADCC was evaluated using the xCELLigence system and LDH release assay in ( A ) cells pre-treated for 2 h with 500 ng/ml of neutralizing antibody to Fas (ZB4), or in ( B ) cells exposed to PBMCs pretreated for 30 min with 100 μM Ac-IETD-CHO. ( C ) Caspase -3/7 activity was determined as described above. Results are expressed as (A, B) mean ± SEM, or (C) mean ± SEM fold-change to respective untreated cells. ** p

    Journal: Oncotarget

    Article Title: miR-143 or miR-145 overexpression increases cetuximab-mediated antibody-dependent cellular cytotoxicity in human colon cancer cells

    doi: 10.18632/oncotarget.7010

    Figure Lengend Snippet: Granzyme B inhibition abrogates cetuximab-mediated ADCC in HCT116 cells HCT116-Empty, HCT116-miR-143 or HCT116-miR-145 cells were exposed to 100 μg/ml cetuximab or PBMCs (20:1) alone, or co-treatment of cetuximab together with PBMCs, or vehicle (control). Cetuximab-mediated ADCC was evaluated using the xCELLigence system and LDH release assay in ( A ) cells pre-treated for 2 h with 500 ng/ml of neutralizing antibody to Fas (ZB4), or in ( B ) cells exposed to PBMCs pretreated for 30 min with 100 μM Ac-IETD-CHO. ( C ) Caspase -3/7 activity was determined as described above. Results are expressed as (A, B) mean ± SEM, or (C) mean ± SEM fold-change to respective untreated cells. ** p

    Article Snippet: To inhibit granzyme B, PBMCs were pre-incubated with 100 μM of Granzyme B inhibitor II, Ac-IETD-CHO (Calbiochem, Merck Millipore, Massachusetts, USA) for 30 min at 37°C, before target cell treatment.

    Techniques: Inhibition, Lactate Dehydrogenase Assay, Activity Assay